Pain Management Therapeutics Market Size, Growth, Demands Outlook and Forecasts to 2030

According to the research report, the global painmanagement therapeutics market size is expected to touch USD 105.77 Billion by 2030, from USD 72.41 Billion in 2021, growing with a significant CAGR of 4.3% from 2022 to 2030.

Pain Management Therapeutics Market Size 2022-2030

The pain management therapeutics market report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global pain management therapeutics market in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global pain management therapeutics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global pain management therapeutics market during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1224

Market Scope

Report Highlights	Details
Market Size	USD 105.77 Billion by 2030
Growth Rate	CAGR of 4.3% from 2022 to 2030
Base Year	2021
Historic Data	2017 to 2021
Forecast Period	2022 to 2030
Segments Covered	Drug Class, Indication, Distribution Channel
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

This study covers a detailed segmentation of the global pain management therapeutics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global pain management therapeutics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

Teva Pharmaceutical
Pfizer
Abbott
Mallinckrodt Pharmaceuticals
Endo International
GlaxoSmithKline
AstraZeneca
Depomed
Merck
Novartis

Market Segmentation

By Drug Class

NSAIDs
Opioids
Anesthetics
Antidepressants
Anticonvulsants
Others

By Indication

Arthritic Pain
Neuropathic Pain
Chronic Back Pain
Post-Operative Pain
Cancer Pain
Others

By Distribution Channel

Online Pharmacy
Retail Pharmacy
Hospital Pharmacy

By Geography

North America
- - U.S.
  - Canada
Europe
- - Germany
  - France
  - United Kingdom
  - Rest of Europe
Asia Pacific
- - China
  - Japan
  - India
  - Southeast Asia
  - Rest of Asia Pacific
Latin America
- - Brazil
  - Rest of Latin America
Middle East & Africa (MEA)
- - GCC
  - North Africa
  - South Africa
  - Rest of Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global pain management therapeutics market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global pain management therapeutics market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pain Management Therapeutics Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pain Management Therapeutics Market

5.1. Covid-19: Pain Management Therapeutics Industry Impact
5.2. Pain Management Therapeutics Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pain Management Therapeutics Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pain Management Therapeutics Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pain Management Therapeutics Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing geriatric population
6.1.2. Market Restraints
6.1.2.1. Side-effects associated with some pain management medications
6.1.3. Market Opportunities
6.1.3.1. Growing research and development expenditure
6.1.3.2. Technological advancements

Chapter 7. Global Pain Management Therapeutics Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pain Management Therapeutics Market Revenue by Market Players (2016 -2019)
7.1.1.2. Pain Management Therapeutics Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Class Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pain Management Therapeutics Market, By Drug Class

8.1. Pain Management Therapeutics Market, by Drug Class, 2017 - 2030
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2017 - 2030)
8.1.2. Opioids
8.1.2.1. Market Revenue and Forecast (2017 - 2030)
8.1.3. Anesthetics
8.1.3.1. Market Revenue and Forecast (2017 - 2030)
8.1.4. Antidepressants
8.1.4.1. Market Revenue and Forecast (2017 - 2030)
8.1.5. Anticonvulsants
8.1.5.1. Market Revenue and Forecast (2017 - 2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017 - 2030)

Chapter 9. Global Pain Management Therapeutics Market, By Indication

9.1. Pain Management Therapeutics Market, by Indication, 2017 - 2030
9.1.1. Arthritic Pain
9.1.1.1. Market Revenue and Forecast (2017 - 2030)
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast (2017 - 2030)
9.1.3. Chronic Back Pain
9.1.3.1. Market Revenue and Forecast (2017 - 2030)
9.1.4. Post-Operative Pain
9.1.4.1. Market Revenue and Forecast (2017 - 2030)
9.1.5. Cancer Pain
9.1.5.1. Market Revenue and Forecast (2017 - 2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2017 - 2030)

Chapter 10. Global Pain Management Therapeutics Market, By Distribution Channel

10.1. Pain Management Therapeutics Market, by Distribution Channel, 2017 - 2030
10.1.1. Online Pharmacy
10.1.1.1. Market Revenue and Forecast (2017 - 2030)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2017 - 2030)
10.1.3. Hospital Pharmacy
10.1.3.1. Market Revenue and Forecast (2017 - 2030)

Chapter 11. Global Pain Management Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Drug Class(2017 - 2030)
11.1.2. Market Revenue Forecast by Indication(2017 - 2030)
11.1.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2017 - 2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2017 - 2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.2.2. Market Revenue Forecast by Indication (2017 - 2030)
11.2.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2017 - 2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2017 - 2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2017 - 2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2017 - 2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.3.2. Market Revenue Forecast by Indication (2017 - 2030)
11.3.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2017 - 2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2017 - 2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2017 - 2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2017 - 2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.4.2. Market Revenue Forecast by Indication (2017 - 2030)
11.4.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2017 - 2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2017 - 2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.5.2. Market Revenue Forecast by Indication (2017 - 2030)
11.5.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2017 - 2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2017 - 2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2017 - 2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2017 - 2030)

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Distribution Channel
12.1.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.1.4. Recent Developments and Strategies
12.2. Pfizer
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Distribution Channel
12.2.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.2.4. Recent Developments and Strategies
12.3. Abbott
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Distribution Channel
12.3.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.3.4. Recent Developments and Strategies
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Distribution Channel
12.4.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.4.4. Recent Developments and Strategies
12.5. Endo International
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Distribution Channel
12.5.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.5.4. Recent Developments and Strategies
12.6. GlaxoSmithKline
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Distribution Channel
12.6.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.6.4. Recent Developments and Strategies
12.7. AstraZeneca
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Distribution Channel
12.7.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.7.4. Recent Developments and Strategies
12.8. Depomed
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Distribution Channel
12.8.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.8.4. Recent Developments and Strategies
12.9. Merck
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Distribution Channel
12.9.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.9.4. Recent Developments and Strategies
12.10. Novartis
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Distribution Channel
12.10.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.10.4. Recent Developments and Strategies